Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment.
Sign Up to like & getrecommendations! Published in 2017 at "Cancer cell"
DOI: 10.1016/j.ccell.2017.02.002
Abstract: We identified B cell maturation antigen (BCMA) as a potential therapeutic target in 778 newly diagnosed and relapsed myeloma patients. We constructed an IgG-based BCMA-T cell bispecific antibody (EM801) and showed that it increased CD3+… read more here.
Keywords: myeloma; cell bispecific; bcma cell; antibody em801 ... See more keywords